/ Suven Life Sciences Secures A Product Patent From USA ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 30 January 2017

Suven Life Sciences has announced that the company has secured a product patent from USA corresponding to the New Chemical Entities (NCEs), for the purpose of the treatment of disorders connected with Neurodegenerative diseases, the patent being valid through 2034.

Suven has in its kitty now a total of 25 granted patents from USA, inclusive of the current patent. The claims of the patents that have been granted are from the mechanism of action, and include a class of selective 5HT6 compounds that are being specifically developed as therapeutic agents. They are utilised in the treatment of Alzheimer’s disease, Huntington’s disease, Major Depressive disorder (MDD), Attention deficient hyperactivity disorder (ADHD), Parkinsons and Schizophrenia, which are cognitive neurodegenerative disorders.

Being a biopharmaceutical company, Suven Life Sciences mainly focuses on discovering, developing and commercialising novel pharmaceutical products that are particularly best in class CNS therapies, and this is done through the application of GPCR targets.

Suven Life Sciences Ltd is currently trading at Rs 178.75, up by Rs 2.2 or 1.25% from its previous closing of Rs 176.55 on the BSE.

The scrip opened at Rs 176.45 and has touched a high and low of Rs 184 and Rs 176.35 respectively. So far 418355(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 2247.17 crore.

The BSE group 'B' stock of face value Rs 1 has touched a 52 week high of Rs 228.5 on 30-May-2016 and a 52 week low of Rs 144.35 on 19-Feb-2016. Last one week high and low of the scrip stood at Rs 178.8 and Rs 170.7 respectively. The promoters holding in the company stood at 60 % while Institutions and Non-Institutions held 7.32 % and 32.68 % respectively. The stock is currently trading above its 200 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717